NASDAQ:CERC Cerecor (CERC) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free CERC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$12.33▼$13.7450-Day Range$2.06▼$3.2452-Week Range$1.98▼$4.50Volume73,223 shsAverage Volume1.27 million shsMarket Capitalization$1.25 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsInsider TradesSocial MediaStock AnalysisCompetitorsInsider TradesSocial Media Get Cerecor alerts: Email Address Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 About Cerecor Stock (NASDAQ:CERC)Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.Read More Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 CERC Stock News HeadlinesDecember 19, 2023 | benzinga.comAytu BioPharma Stock (NASDAQ:AYTU) Insider TradesAugust 24, 2023 | uk.finance.yahoo.commTOR Inhibitors Global Market Report 2023April 23, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinMay 11, 2023 | finance.yahoo.comDelveInsight Highlights Major Advances, Transformative Therapies, and 80+ Leading Players Wheeling the Crohn's Disease Pipeline LandscapeSeptember 28, 2022 | finance.yahoo.comEdited Transcript of AYTU.OQ earnings conference call or presentation 27-Sep-22 8:30pm GMT - Yahoo FinanceSeptember 28, 2022 | seekingalpha.comAytu BioPharma, Inc. (AYTU) CEO Josh Disbrow on Q4 2022 Results - Earnings Call Transcript - Seeking AlphaAugust 31, 2022 | marketwatch.comDiGeorge Syndrome Drug Market In-Depth Analysis Research Report 2029August 24, 2022 | streetinsider.comValenzaBio Appoints Industry Veteran Peter Greenleaf to its Board of Directors - StreetInsider.comApril 23, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinAugust 24, 2022 | businesswire.comValenzaBio Appoints Industry Veteran Peter Greenleaf to its Board of Directors - Business WireAugust 11, 2022 | globenewswire.comCelldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update - GlobeNewswireAugust 9, 2022 | streetinsider.comCelldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update - StreetInsider.comAugust 8, 2022 | marketscreener.comCelldex Therapeutics : Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Form 8-K - Marketscreener.comJuly 24, 2022 | seekingalpha.comAvalo Therapeutics, Inc. (AVTX) Stock Price Today, Quote & News - Seeking AlphaJuly 15, 2022 | bizjournals.comPhiladelphia biotech news: Updates from CHOP, Helius Medical, GSK and more - Philadelphia Business Journal - The Business JournalsMay 3, 2022 | prnewswire.comThe Axial Spondyloarthritis Market is Predicted to Grow with a CAGR of 4.7% by 2032, Analyzes DelveInsight - PR NewswireMay 1, 2022 | marketwatch.comDiGeorge Syndrome Drug Market Size, Share, Industry Growth & Forecast By 2029April 8, 2022 | marketscreener.comAACR Poster Presentation: CFT7455 Phase 1/2 Cohort A - Marketscreener.comMarch 28, 2022 | benzinga.comDiGeorge Syndrome Drug Market High Demand, Size, Share, Processing Industry, And Forecast By 2029 - Benzi - BenzingaNovember 10, 2021 | businesswire.comModel N Announces Fourth Quarter and Fiscal Year 2021 Financial Results - Business WireNovember 10, 2021 | nasdaq.comModel N (MODN) Q4 Earnings & Revenues Top Estimates, Up Y/Y - NasdaqNovember 9, 2021 | finance.yahoo.comModel N Announces Fourth Quarter and Fiscal Year 2021 Financial Results - Yahoo FinanceNovember 9, 2021 | finance.yahoo.comAvalo Reports Third Quarter 2021 Financial Results and Provides Business Updates - Yahoo FinanceNovember 9, 2021 | stockhouse.comModel N Announces Fourth Quarter and Fiscal Year 2021 Financial Results - StockhouseOctober 7, 2021 | finance.yahoo.comHorizon Technology Finance Provides Third Quarter 2021 Portfolio Update - Yahoo FinanceAugust 27, 2021 | bizjournals.comInovio's experimental Covid-19 vaccine takes another step, plus other life sciences news - Philadelphia Business Journal - Philadelphia Business JournalAugust 27, 2021 | marketscreener.comCERECOR : Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc (Form 8-K) - Marketscreener.comSee More Headlines Receive CERC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerecor and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2021Today4/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CERC CUSIPN/A CIK1534120 Webwww.cerecor.com Phone(410) 522-8707FaxN/AEmployees31Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,500,000.00 Net Margins-1,194.82% Pretax MarginN/A Return on Equity-261.82% Return on Assets-133.96% Debt Debt-to-Equity Ratio0.79 Current Ratio2.19 Quick Ratio2.18 Sales & Book Value Annual Sales$6.70 million Price / Sales174.97 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book55.50Miscellaneous Outstanding Shares96,009,000Free FloatN/AMarket Cap$1.17 billion OptionableNot Optionable Beta1.44 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMichael F. ColaChairman & Chief Executive OfficerSchond L. GreenwayChief Financial Officer & TreasurerH. Jeffrey WilkinsChief Medical OfficerGarry Arthur NeilChief Scientific OfficerYounok Dumortier ShinChief Technology OfficerKey CompetitorsProtagonist TherapeuticsNASDAQ:PTGXEdgewise TherapeuticsNASDAQ:EWTXDynavax TechnologiesNASDAQ:DVAXArdelyxNASDAQ:ARDXTaro Pharmaceutical IndustriesNYSE:TAROView All Competitors CERC Stock Analysis - Frequently Asked Questions How were Cerecor's earnings last quarter? Cerecor Inc. (NASDAQ:CERC) released its quarterly earnings results on Sunday, August, 1st. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The firm had revenue of $3.36 million for the quarter. Cerecor had a negative net margin of 1,194.82% and a negative trailing twelve-month return on equity of 261.82%. What other stocks do shareholders of Cerecor own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cerecor investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), KushCo (KSHB), Novan (NOVN), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI). This page (NASDAQ:CERC) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsMan Who Predicted 2008: “This Will be Worse.”AltimetryGreat Crypto BullWeiss RatingsThe Next Nvidia?InvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersBiden out June 13; Kamala won’t replace him?Paradigm PressNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerecor Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
